A number of other research analysts have also issued reports on BPMC. Raymond James increased their target price on Blueprint Medicines from $95.00 to $106.00 and gave the company a “strong-buy” rating in a research report on Tuesday, July 14th. HC Wainwright lifted their target price on shares of Blueprint Medicines from $66.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. Morgan Stanley upped their price target on shares of Blueprint Medicines from $88.00 to $92.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 15th. ValuEngine lowered Blueprint Medicines from a “strong-buy” rating to a “buy” rating in a research note on Friday, May 1st. Finally, SVB Leerink lifted their price target on Blueprint Medicines from $106.00 to $107.00 and gave the stock an “outperform” rating in a research note on Monday, July 27th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $96.15.
BPMC opened at $73.18 on Friday. The company has a fifty day moving average of $76.68 and a two-hundred day moving average of $67.22. The stock has a market capitalization of $3.97 billion, a price-to-earnings ratio of -9.54 and a beta of 1.09. Blueprint Medicines has a fifty-two week low of $43.29 and a fifty-two week high of $101.76. The company has a debt-to-equity ratio of 0.13, a quick ratio of 7.14 and a current ratio of 7.17.
Blueprint Medicines (NASDAQ:BPMC) last posted its earnings results on Thursday, July 30th. The biotechnology company reported ($2.28) EPS for the quarter, missing the Zacks’ consensus estimate of ($2.08) by ($0.20). The business had revenue of $8.34 million for the quarter, compared to analyst estimates of $7.56 million. Blueprint Medicines had a negative net margin of 525.44% and a negative return on equity of 71.24%. On average, equities research analysts forecast that Blueprint Medicines will post -3.79 earnings per share for the current year.
In other news, Director Nicholas Lydon sold 13,017 shares of Blueprint Medicines stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $80.29, for a total value of $1,045,134.93. Following the completion of the sale, the director now directly owns 89,039 shares of the company’s stock, valued at $7,148,941.31. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Jeffrey W. Albers sold 20,000 shares of the business’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $64.67, for a total value of $1,293,400.00. Following the completion of the sale, the chief executive officer now owns 161,434 shares in the company, valued at approximately $10,439,936.78. The disclosure for this sale can be found here. Insiders sold a total of 66,349 shares of company stock worth $5,001,908 over the last three months. Insiders own 3.81% of the company’s stock.
Several institutional investors and hedge funds have recently modified their holdings of BPMC. Bourgeon Capital Management LLC purchased a new position in Blueprint Medicines in the 1st quarter valued at approximately $29,000. Advisor Group Holdings Inc. acquired a new stake in Blueprint Medicines in the first quarter valued at $32,000. Exane Derivatives raised its stake in Blueprint Medicines by 35,300.0% in the first quarter. Exane Derivatives now owns 1,770 shares of the biotechnology company’s stock valued at $104,000 after buying an additional 1,765 shares in the last quarter. Cutler Group LP lifted its holdings in Blueprint Medicines by 480.0% during the 1st quarter. Cutler Group LP now owns 1,900 shares of the biotechnology company’s stock worth $111,000 after buying an additional 2,400 shares during the last quarter. Finally, Stifel Financial Corp acquired a new position in shares of Blueprint Medicines during the 4th quarter worth about $275,000. 97.96% of the stock is currently owned by institutional investors and hedge funds.
About Blueprint Medicines
Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which completed Phase I clinical trials that targets PDGFRA Exon 18 mutant GIST and KIT-driven GIST; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.
Recommended Story: What is Green Investing?
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.